RUSHB:NASDAQRush Enterprises, Inc. Analysis
Data as of 2026-04-29 - not real-time
$76.65
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Rush Enterprises is trading at $76.65, comfortably above its 20‑day, 50‑day and 200‑day simple moving averages, indicating a strong bullish trend. The 14‑day RSI sits near 71, signaling that the stock is technically overbought. The MACD line remains above its signal line, producing a bullish histogram, yet the recent decrease in volume suggests waning buying momentum. Current price is perched just below the identified resistance at $79.13 and well above the support level of $61.70, leaving limited upside before a potential pull‑back. With a beta of roughly 0.96 and a 30‑day volatility of 27%, the equity exhibits market‑aligned risk but higher short‑term price swings.
On the valuation side, the market price exceeds the discounted cash‑flow fair value of about $50, and a trailing P/E of 23× places the stock in the overvalued quadrant. Fundamentally, the company posted $1.68 billion in revenue for Q1, a 9 % YoY decline, and earnings per diluted share of $0.77, missing consensus expectations. Gross margins hover around 20 % and operating margins just over 5 %, reflecting a low‑margin business model. Nevertheless, operating cash flow of $862 million and a free cash flow of $389 million support the current dividend yield of 0.98 % with a modest payout ratio of 22 %. The balance sheet shows $1.44 billion of debt against $213 million of cash, resulting in a debt‑to‑equity ratio near 65 %, which is manageable but warrants monitoring.
Recent news confirms the earnings miss and the declaration of a $0.19 per share cash dividend, underscoring the company’s commitment to shareholders despite the revenue headwinds. In summary, the stock’s technical strength is offset by overvaluation, declining sales and cyclical sector exposure, suggesting limited upside in the near term and heightened risk over longer horizons.
On the valuation side, the market price exceeds the discounted cash‑flow fair value of about $50, and a trailing P/E of 23× places the stock in the overvalued quadrant. Fundamentally, the company posted $1.68 billion in revenue for Q1, a 9 % YoY decline, and earnings per diluted share of $0.77, missing consensus expectations. Gross margins hover around 20 % and operating margins just over 5 %, reflecting a low‑margin business model. Nevertheless, operating cash flow of $862 million and a free cash flow of $389 million support the current dividend yield of 0.98 % with a modest payout ratio of 22 %. The balance sheet shows $1.44 billion of debt against $213 million of cash, resulting in a debt‑to‑equity ratio near 65 %, which is manageable but warrants monitoring.
Recent news confirms the earnings miss and the declaration of a $0.19 per share cash dividend, underscoring the company’s commitment to shareholders despite the revenue headwinds. In summary, the stock’s technical strength is offset by overvaluation, declining sales and cyclical sector exposure, suggesting limited upside in the near term and heightened risk over longer horizons.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- RSI overbought
- Approaching resistance $79.13
- Decreasing volume
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Bullish SMA alignment
- Overvalued relative to DCF
- Sustained dividend
Long Term
> 3 yearsCautious
Model confidence: 8/10
Key Factors
- Revenue decline
- Valuation gap
- Cyclical sector exposure
Key Metrics & Analysis
Financial Health
Revenue Growth-11.80%
Profit Margin3.55%
P/E Ratio23.4
ROE12.13%
ROA5.43%
Debt/Equity64.81
P/B Ratio2.7
Op. Cash Flow$861.8M
Free Cash Flow$389.2M
Technical Analysis
TrendBullish
RSI70.8
Support$61.70
Resistance$79.13
MA 20$71.78
MA 50$66.40
MA 200$58.94
MACDBullish
VolumeDecreasing
Fear & Greed Index89.59
Valuation
Fair Value$50.29
GradeOvervalued
TypeValue
Dividend Yield0.98%
Risk Assessment
Beta0.96
Volatility27.21%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.